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Neurological, Psychiatric, and 
Biochemical Aspects of Thiamine 
Deficiency in Children and Adults
Shibani Dhir 1†, Maya Tarasenko 1†, Eleonora Napoli 1 and Cecilia Giulivi 1,2*
1 Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States, 
2 Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis, Davis, CA, United States
Thiamine (vitamin B1) is an essential nutrient that serves as a cofactor for a number of 
enzymes, mostly with mitochondrial localization. Some thiamine-dependent enzymes are 
involved in energy metabolism and biosynthesis of nucleic acids whereas others are part 
of the antioxidant machinery. The brain is highly vulnerable to thiamine deficiency due 
to its heavy reliance on mitochondrial ATP production. This is more evident during rapid 
growth (i.e., perinatal periods and children) in which thiamine deficiency is commonly 
associated with either malnutrition or genetic defects. Thiamine deficiency contributes 
to a number of conditions spanning from mild neurological and psychiatric symptoms 
(confusion, reduced memory, and sleep disturbances) to severe encephalopathy, ataxia, 
congestive heart failure, muscle atrophy, and even death. This review discusses the 
current knowledge on thiamine deficiency and associated morbidity of neurological and 
psychiatric disorders, with special emphasis on the pediatric population, as well as the 
putative beneficial effect of thiamine supplementation in autism spectrum disorder (ASD) 
and other neurological conditions.
Keywords: autism spectrum disorders, brain, depressive disorders, encephalomyopathies, Krebs cycle, pentose 
phosphate pathway, thiamine transporter
INTRODUCTION
The essential nutrient thiamine (vitamin B1) is a water-soluble, sulfur-containing vitamin belonging 
to the vitamin B complex family (Figure 1A). Not being endogenously synthesized, the only available 
source of thiamine is dietary (beef, poultry, cereals, nuts, and beans). The body does not store 
thiamine in levels >30 mg, and the half-life for thiamine is only 9–18 days. For an average of ~2,000 
kcal consumed daily, the minimum thiamine requirement is calculated at 0.66 mg (1), although 
the recommended daily intake for adult men and women is 1.2 and 1.1 mg, respectively (1,  2). 
During pregnancy or breast-feeding, this requirement increases to 1.4 mg/day (1). In children, the 
recommended dietary allowance (RDA) is age-dependent and spanning from 0.2 mg (from birth up 
to 6 months old) to 0.6 mg (from 6 months old to 8 years old) (3). In the human body, thiamine-rich 
tissues are skeletal muscles, heart, liver, kidney, and brain (4).
Despite the availability of dietary thiamine in wealthy countries, thiamine deficiency 
represents an important and usually overlooked issue. In developed countries, the predominant 
use of industrial food processing often depletes thiamine content along with other vitamins and 
nutrients. An increased consumption of processed food in the form of simple carbohydrates, not 
supplemented with adequate levels of thiamine, has been named “high calorie malnutrition” (7, 8). 
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Thus, despite the caloric density, the diet is often of poor nutrition 
quality and does not meet recommended dietary guidelines for 
micronutrient intake, making this an at-risk population for 
micronutrient malnutrition (8). For instance, at least 29% of 
obese subjects that will undergo bariatric surgery have been 
reported as thiamine deficient (9). This condition highlights 
the fine balance between adequate caloric intake and balanced 
nutritional diet. As thiamine is a key factor in the metabolism 
of glucose, an increased carbohydrate intake will proportionally 
increase thiamine’s dietary demand (a minimum of 0.33 mg per 
FIGURE 1 | Thiamine metabolism. (A) Chemical structure of thiamine and phosphorylated derivatives. (B) Absorption and cellular uptake of thiamine. 
Dietary thiamine is mainly in the form of phosphate derivatives and, before absorption, these are converted to free thiamine by intestinal phosphatases. 
Mammalians utilize THTR1 and THTR2 to transport thiamine. The THTR1 appears to function in the micromolar range, whereas the THTR-2 appears to 
function in the nanomolar range. Both transporters are expressed in the human small and large intestine, and the expression of THTR1 is higher than that of 
THTR2, with THTR1 found at both the apical and basolateral membranes of enterocytes (somewhat higher expression at the latter compared to the former 
domain). Expression of the THTR2 protein was found to be restricted to the apical membrane domain only [see (5) and references therein]. Free thiamine is 
converted to TPP by the action of TPK1 in the cytosol and dephosphorylation of TPP to TMP and thiamine by ACPP. At higher concentrations of thiamine, 
simple passive diffusion takes place [see (6) and references therein]. From blood, thiamine is taken up by either transporter (THTR1 or THTR2). Both carriers 
are widely distributed in the body, but the levels differ in different tissues. Once inside the target cells, thiamine is phosphorylated to TPP by TPK1 and to 
TTP by TDPK. Both TPP and TTP can be dephosphorylated by ACPP and THTPA, respectively. TPP in the cytosol is utilized as a cofactor for TKT, but it 
is also required as a cofactor in the mitochondrial compartment; hence, the mitochondrial SLC25A19 exists at the inner mitochondrial membrane. TPP 
must be bound to HACL1 and HACL2 for its transport to the peroxisomes. Abbreviations: ACPP, prostatic acid phosphatase; ADP, adenosine diphosphate; 
AMP, adenosine monophosphate; ATP, adenosine triphosphate; T, thiamine; TDPK, thiamine diphosphokinase; THTPA, thiamine triphosphatase; THTR, 
thiamine transporter; TMP, thiamine monophosphate; TPP, thiamine pyrophosphate. (C) Pathways involving TPP-dependent enzymes. In the cytosol, TPP 
is the cofactor of transketolase (TKT), an enzyme involved in the pentose phosphate pathway (PPP). The PPP produces nicotinamide adenine dinucleotide 
phosphate (NADPH) and ribose 5-phosphate (R5P), essential for antioxidant defense and fatty acid synthesis, and precursor in the biosynthesis of 
nucleotides, respectively. In mitochondria, TPP acts as a cofactor for branched-chain α-ketoacid dehydrogenase (BCKDH) complex, pyruvate dehydrogenase 
(PDH) complex, and α-ketoglutarate dehydrogenase. In peroxisomes, TPP is a cofactor for 2-hydroxyacyl-CoA lyase 1 (HACL1) as part of the fatty acid 
α-oxidation pathway.
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1,000 kcal) (1). Thus, rather than focusing on thiamine’s RDA, it 
is critical to match its intake with carbohydrate consumption as 
well as total caloric intake.
In developing countries, thiamine deficiency remains a 
widespread concern due to high rates of white rice consumption 
(3). As home-pounding techniques are replaced with industrial 
rice milling and processing, essential nutrients (such as thiamine) 
within the bran are stripped away (10). Asian countries consume 
about 90% of the rice produced worldwide, fulfilling an estimated 
60% of the population’s daily dietary energy intake requirement, 
and consequently, thiamine deficiency has become prevalent 
in the 15% of the adolescent population (using the most 
conservative approximation) (11). Thiamine deficiency may 
develop by ingesting diets either contaminated with thiamine-
metabolizing enzymes (e.g., thiaminase) (12) or that underwent 
thiamine inactivation by heat and/or sulfur dioxide (13). Heavy 
consumption of tannin-containing or food rich in caffeine, 
theobromine, and theophylline (such as those present in coffee, 
chocolate, and tea, respectively) can inactivate thiamine, thereby 
compromising the thiamine status (7, 14, 15).
Other risk factors that increase the likelihood of insufficient 
thiamine intake include aging, economic status, eating disorders, 
medical conditions affecting the gastrointestinal tract, subjects 
receiving parental nutrition, bariatric surgery, diabetes, and 
alcohol abuse (9, 16–23). Unmet needs for increasing the 
nutritional intake of thiamine are reported during lactation, 
pregnancy, and increased physical activity (11, 24). During 
lactation, infants have increased risks of developing beriberi from 
newly deficient but asymptomatic mothers (11). For instance, 
27% of women of childbearing age are considered thiamine 
deficient in Cambodia, with 38% of infants being diagnosed as 
severely deficient in thiamine, a critical issue that contributes 
significantly to the mortality of 3-month-old babies (11).
However, even in the presence of an adequate thiamine intake, 
its deficiency can result from genetic factors, i.e., pathogenic 
gene mutations in key regulators of the thiamine pathway, 
including thiamine pyrophosphokinase 1 (TPK1), thiamine 
diphosphate kinase (TDPK), thiamine triphosphatase (THTPA), 
and thiamine transporters (SLC25A19, SLC19A2/THTR1, 
and SLC19A3/THTR2; Figure 1B). More recently, the organic 
cation transporter 1 (OCT1) has been claimed to act as a hepatic 
thiamine transporter (25).
Regardless of the underlying cause, thiamine deficits may 
have severe detrimental effects, with most of the symptoms 
manifesting at the neurological level (24, 26). Thiamine deficiency 
might cause brain tissue injury by inhibiting brain energy 
utilization given the critical role of thiamine-dependent enzymes 
associated within glucose utilization (27). This is supported 
by the significant rate of thiamine uptake by the blood–brain 
barrier emphasizing the high brain demand for thiamine and the 
need for its supply to sustain adequate brain functions (28, 29), 
especially in those brain areas with both high metabolic demands 
and high thiamine turnover (30–32).
This review will discuss the physiological and biochemical 
bases of thiamine metabolism and explore the pathophysiological 
implications of thiamine deficiency. In particular, we will 
highlight the effect of thiamine supplementation as a therapeutic 
strategy in the management of neurological disorders, with 
special emphasis on the pediatric population.
BIOCHEMICAL BASIS OF THIAMINE’S 
CELLULAR ROLE
Dietary Availability, Absorption, 
and Cellular Uptake
As with most hydrophilic micronutrients, thiamine absorption 
occurs mainly in the jejunum (33). Throughout the digestive 
tract, dietary proteins get hydrolyzed, releasing thiamine. In the 
intestinal lumen, alkaline phosphatases catalyze the hydrolysis 
of thiamine-phosphorylated derivatives into free thiamine (34). 
Unphosphorylated, free thiamine at concentrations higher than 
1 µM enters the enterocyte by passive diffusion, whereas at lower 
levels, it is transported via the saturable thiamine/H+ antiport 
system (thiamine transporter 1 or THTR1) through an energy-
dependent process (33). Under conditions of thiamine deficiency, 
an upregulation of the expression of the thiamine transporter 
2 (THTR2) was observed in Caco2 cells in culture, suggesting 
that diet can modulate the expression of this transporter 
(35). Within the enterocyte, thiamine is phosphorylated to 
thiamine pyrophosphate (TPP) by TPK1. Then, most TPP is 
dephosphorylated to thiamine monophosphate (TMP) to cross 
the basal membrane of the enterocyte. The TMP is released into 
the bloodstream through an ATPase-dependent transport system 
(36) (Figure 1B). Free thiamine can also reach the bloodstream 
via the thiamine transporter 2 (THTR2) located mainly at the 
basolateral membrane of the enterocyte. Once in blood, while very 
low levels of TMP and thiamine circulate free in plasma or serum, 
more than 90% of the phosphorylated thiamine (in the form of 
TPP) is present in erythrocytes and leukocytes (37). Notably, the 
isoform 3 of the carrier SLC44A4 has recently been described as 
a TPP carrier in the colon. Originally, SLC44A4 was described 
as a choline transporter linked to the non-neuronal synthesis of 
choline (38) and required to the efferent innervation of hair cells 
in the olivocochlear bundle for the maintenance of physiological 
function of outer hair cells and the protection of hair cells from 
acoustic injury (39). Recent evidence indicates that this carrier may 
mediate the absorption of microbiota-generated TPP (especially in 
infants) and contribute to host thiamine homeostasis (40).
The cellular uptake of thiamine from the bloodstream can 
be mediated by any of the two high-affinity carriers: THTR1 
[encoded by SLC19A2 (41)] and THTR2 [encoded by SLC19A3 
(42, 43)]. These transporters are ubiquitously expressed (42–44), 
but THTR1 is most abundant in the intestine, skeletal muscle, 
nervous system, and eye followed by the placenta, liver, and kidney, 
whereas THTR2 is located mostly in adipose tissue, breast tissue, 
liver, lymphocytes, spleen, gallbladder, placenta, pancreas, and 
brain (information collected from GeneCards). Once transported 
intracellularly, free thiamine is rapidly phosphorylated to TPP by 
thiamine pyrophosphokinase (TPK1). A second kinase, TDPK, 
adds a phosphate group to TPP to generate thiamine triphosphate 
(TTP). TPP and TTP can be dephosphorylated to, respectively, 
TMP and TPP by phosphatases [Prostatic Acid Phosphatase 
(ACPP) and THTPA, respectively; Figure 1B].
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Biochemical Roles of Phosphorylated 
Forms of Thiamine
Up to 90% of the total thiamine in the body remains in its 
diphosphate, metabolically active form (TPP), whereas the rest is 
found as TMP and TTP (45). TPP is a cofactor of several thiamine-
dependent enzymes involved in carbohydrate and fatty acid 
metabolism, namely, cytosolic transketolase (TKT), peroxisomal 
2-hydroxyacyl-CoA lyase 1, and three mitochondrial enzymes 
(pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and 
branched-chain α-ketoacid dehydrogenase complexes; Figure 1C). 
As the biochemical role of TPP is well understood, the biological 
significance and contribution of TTP is not entirely clear. It 
was previously considered to be a specific neuroactive form of 
thiamine, but more recently, it has been reported that TTP (which 
is ~10% of the total brain thiamine pool) is involved in membrane 
excitability and nerve conduction by acting as a modulator of the 
permeability of sodium chloride channels (29, 32, 46).
Intracellular Location of TPP-Dependent Enzymes
Cytosol
In the cytosol, TPP acts as a cofactor for TKT, a key enzyme 
of the non-oxidative branch of the pentose phosphate pathway 
(PPP). This metabolic pathway generates nicotinamide adenine 
dinucleotide phosphate (NADPH) and ribose 5-phosphate (R5P) 
(47). NADPH is a key reducing agent in biosynthetic reactions 
and is a co-substrate of biosynthetic enzymes (fatty acid synthesis) 
and antioxidant enzymes such as the glutathione peroxidase–
reductase system and thioredoxin peroxidases, among others. The 
crucial involvement of R5P in the biosynthesis of DNA and RNA 
highlights the critical role of thiamine in high-proliferating tissues.
Based on its role in the abovementioned biochemical 
pathways, it is expected that thiamine deficiency will result in 
increased oxidative stress and lower cell proliferation, as well 
as decreased fatty acid synthesis (including myelin) with severe 
consequences especially during brain development. Consistent 
with this premise, thiamine deficiency decreases TKT activity 
and leads to PPP impairment and reduced neurogenesis in 
murine cortex and hippocampus during neurodevelopment (48).
Peroxisomes
Peroxisomes play an important role in the catabolism of hydrogen 
peroxide, as well as in the shortening of very long fatty acids (which 
cannot undergo a direct mitochondrial β-oxidation catabolism) 
and α-oxidation (49). In the latter process, the TPP-dependent 
enzyme 2-hydroxyacyl-CoA lyase 1 (HACL1) catalyzes the cleavage 
of 3-methyl-branched and straight chain 2-hydroxy long-chain 
fatty acids (50). Phytanic acid (a 3-methyl-substituted, 20-carbon 
branched-chain fatty acid), unlike most fatty acids, is unable to 
undergo β-oxidation because of an existing methyl group in the 
3-position (51). As such, it is broken down by HACL1 by an initial 
α-oxidation (52, 53). This branched-chain fatty acid is obtained 
through the diet, specifically from dairy products and red meat. The 
disruption of phytanic acid catabolism, due to inadequate levels of 
TPP, leads to triglyceride accumulation, which may cause deleterious 
effects such as cerebellar ataxia, peripheral polyneuropathy, 
vision and hearing loss, anosmia, and, in some instances, cardiac 
dysfunction and epiphyseal dysplasia (54). The symptoms caused 
by thiamine deficiency are shared by Refsum’s disease, which 
is caused by pathogenic mutations in HACL1 (55). Some of the 
symptoms are also observed in the autosomal recessive systemic 
disorder Zellweger syndrome and other peroxisomal-related 
diseases including the neonatal adrenoleukodystrophy. Zellweger 
syndrome is caused by pathogenic mutations in the pexin genes, 
which encode for proteins essential for the assembly of functional 
peroxisomes. It is characterized by deficits in the peroxisomal 
fatty acid oxidation pathway causing severe neurological and liver 
dysfunction as well as craniofacial abnormalities.
Mitochondria
Most (~90%) of the cytosolic TPP is transported into mitochondria 
via the mitochondrial thiamine pyrophosphate transporter 
[MTPPT, product of the SLC25A19 gene (56)]. This transporter 
mediates the exchange of cytosolic TPP for the mitochondrial 
TMP; once in the cytosol, TMP is metabolized and converted 
back to TPP (56). In mitochondria, TPP is a critical cofactor for 
three enzymes, namely, pyruvate dehydrogenase, α-ketoglutarate 
dehydrogenase, and branched-chain α-ketoacid dehydrogenase 
(PDH, αKGDH, and BCKDH, respectively).
Studies in SLC25A19 knockout mice and in carriers of 
the SLC25A19 mutation, responsible for the Amish lethal 
microcephaly (MCPHA, see below) show, respectively, virtually 
undetectable and markedly reduced mitochondrial TPP levels 
in mouse embryonic fibroblasts and human lymphoblasts (56), 
which were completely restored upon addition of TPP to the 
PDH and KGDH complex assay mixtures (56).
Pyruvate dehydrogenase complex. This multisubunit complex 
catalyzes the TPP-dependent decarboxylation of pyruvate, generating 
acetyl-CoA, which then enters the Krebs cycle. The regulation of PDH 
activity constitutes a key metabolic switch influencing fuel choice, 
i.e., between fatty acid oxidation and glycolytic flux (57). The inability 
to adjust the choice of fuel for metabolic energy production has been 
proposed to underlie the “metabolic inflexibility” leading to the 
morbidity of metabolic disorders (58). Hence, thiamine-deficiency-
mediated inhibition of the PDH complex will lock the system into 
the oxidation of glucose to pyruvate, leading to increases in lactate 
and decreases in cellular ATP production (59). As expected, in 
severe cases, the metabolic deficit presents as a fatal lactic acidosis in 
newborns, whereas in milder cases, neurological conditions may 
lead to structural abnormalities in the central nervous system 
(CNS), seizures, mental disability, and spasticity (60, 61).
α-Ketoglutarate dehydrogenase complex. This TPP-
dependent enzyme catalyzes the formation of succinyl-CoA from 
α-ketoglutarate in the Krebs cycle and the consequent production 
of reduced nicotinamide adenine dinucleotide (NADH). Low TPP 
levels notably decrease αKGDH activity, thereby decreasing energy 
production and causing glutamate to accumulate (62), hampering 
oxidative metabolism and leading to neurodegeneration (63).
Branched-chain α-keto dehydrogenase complex. The TPP-
dependent BCKDH enzyme, localized at the inner mitochondrial 
membrane, catalyzes one of the steps of the essential branched-
chain amino acid (BCAAs; leucine, isoleucine, and valine) catabolic 
pathway. These amino acids are required for protein synthesis, 
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and  some of their catabolic products can be used for energy 
production via the citric acid cycle. In addition, their carbon 
skeletons (except Leu) can be used as precursors for gluconeogenesis 
(64). In a thiamine deficiency experimental model, medial thalamus 
was the brain region that shows the lowest levels of BCKDH with 
fivefold accumulation of Leu. This study suggested that the lower 
activity of this enzyme may be responsible for thalamic neuronal 
cell death observed in human cases of thiamine deficiency (65).
Similarly, a homozygous mutation in the BCKDH E1 α subunit 
results in the so-called maple syrup urine disease (MSUD, due to 
the distinct maple syrup smell to the urine as a result of keto acid 
buildup from unprocessed BCAA), characterized by physical 
and mental disabilities. A mild form of MSUD, called thiamine-
responsive MSUD, is currently the only recognized variant 
that can be successfully treated with thiamine supplementation 
(OMIM 248600).
HIERARCHICAL ORDER OF THIAMINE-
DEPENDENT ENZYMATIC DEFICIENCIES: 
EFFECT OF SPECIES, TISSUE, AND 
SUBCELLULAR COMPARTMENT
While it could be assumed that a deficiency in a given 
micronutrient affects its dependent enzymes equally, experimental 
evidence indicates otherwise. For instance, copper deficiency 
severely reduces cytochrome c oxidase activity affecting copper/
zinc-superoxide dismutase to a lesser extent (66). Moreover, this 
hierarchical order is also tissue-specific as different brain areas 
(66). Similarly, in the case of thiamine deficiency, the most affected 
brain regions seem to be cerebellum, mammillary bodies, thalamus, 
hypothalamus, and brainstem in adults (1, 67). In children, MRI 
studies showed primary involvement of mammillary bodies as well 
as basal ganglia (68, 69) [preferentially the striatum and, to a lesser 
extent, the globus pallidus (68)], in addition to frontal lobes (69).
With regard to thiamine deficiency, Zhao et al. showed that, in 
mice, thiamine deprivation for 14 days led to different degrees of 
enzymatic deficiencies when testing for TKT, PDH, and αKGDH 
activities in the cortex and hippocampus (48). TKT activity 
was significantly more reduced in both brain regions compared 
to both mitochondrial enzymes PDH and αKGDH (48). Two 
studies reporting on a genetic mutation in SLC19A3.1 resulted in 
thiamine-deficient Alaskan huskies (26, 70). A greater reduction 
in TKT versus PDH activity was observed in the cortex. In the 
thalamus, however, PDH activity was affected twice as much as 
TKT activity (26). These studies support the concept of tissue-
specific deficits of thiamine deficiency and also point to the 
species-specific differences that should be taken into account 
when making extrapolations to human studies.
In cases of severe thiamine deficiency, however, a broad 
enzymatic deficiency encompassing all three mitochondrial TPP-
dependent enzymes would be expected to result in symptoms 
similar to those of the genetic disorder dihydrolipoamide 
dehydrogenase (DLDD) deficiency (OMIM 246900). This 
pathogenic mutation affects the E3 subunit, common to all three 
TPP-dependent dehydrogenases. Patients clinically present with 
lactic acidosis and neurodegeneration from inefficient oxidative 
metabolism, as well as increased BCAA concentrations and α-keto 
acids in the urine, with many of the same symptoms as MSUD, but 
with a more severe phenotype (71).
While BCKDH and HACL1 are (as indicated above) TPP-
dependent enzymes, their activity is rarely reported in the 
context of thiamine deficiency, with the majority of studies 
focusing on TKT and PDH or αKGDH as indicators of oxidative 
stress (TKT) and mitochondrial dysfunction (PDH or αKGDH). 
However, a study by Navarro et al. noted significantly reduced 
BCKDH activity in the medial thalamus (compared to frontal 
cortex) accompanied by a fivefold increase in Leu levels following 
administration of a thiamine antagonist (65).
The consequences of thiamine deficiency on HACL1, however, 
remain mostly obscure. Recent work in HACL1-deficient mice 
revealed the presence of an additional TPP-dependent enzyme with 
lyase activity, localized in the endoplasmic reticulum, able to cleave 
2-hydroxyphytanoyl-CoA (72). This process is not exactly like the one 
catalyzed by the peroxisomal HACL1 and involves a hydroxylation 
at position C2 carried out by the fatty acid 2-hydroxylase (FA2H), 
followed by the cleavage catalyzed by HACL1 (73). More recently, 
an orphan enzyme (HACL2) located in the endoplasmic reticulum 
known as bacterial acetolactate synthase-like was reported to 
cleave straight chain 2-hydroxyacyl-CoAs (74), and it is likely to be 
identical to the HACL1-like enzyme. A strong inverse association of 
C17:0 with diabetes and cardiovascular risk has been observed, 
suggesting a metabolic link between α-oxidation and these 
diseases (75, 76). More research is needed to elucidate the role 
of HADCL1 and HADCL2 in the context of thiamine deficiency.
DEFECTS IN GENES ASSOCIATED 
WITH THIAMINE METABOLISM
Pathogenic mutations in genes encoding for enzymes and 
transporters involved in thiamine metabolism result in symptoms 
similar to those found in nutrition-based thiamine deficiency and 
overlaps with disorders of mitochondrial dysfunction (Table  1). 
Those mutations affecting genes responsible for thiamine 
transporters 1 (SLC19A2; OMIM 249270) and 2 (SLC19A3; OMIM 
607483) constitute the main cause of suboptimal intestinal thiamine 
absorption and, as a result, insufficient cellular distribution of 
thiamine through the body.
Carriers of homozygous or compound heterozygous loss-
of-function or missense mutations in SLC19A2 develop a rare 
condition known as thiamine-responsive megaloblastic anemia 
(TRMA) or Rogers syndrome (OMIM 249270). Most cases are 
currently found in isolated populations with consanguineous 
partners (85). This early-onset, autosomal recessive disorder is 
characterized by megaloblastic anemia, macrocytosis, diabetes 
mellitus, and sensorineural deafness. Other, more variable 
features include optic atrophy, congenital heart defects, short 
stature, and significant neurological deficits such as stroke and 
epilepsy during infancy (77, 86). The term “thiamine-responsive” 
refers to the observation of clinical, symptomatic improvement 
after administration of high doses of thiamine (86, 87).
The biotin–thiamine-responsive basal ganglia disease (BTBGD; 
OMIM: 607483) is a neurometabolic autosomal recessive disorder 
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caused by a mutation in the SLC19A3 gene, characterized by 
subacute encephalopathy with confusion, convulsions, muscle 
rigidity, ataxia, dysarthria, and dystonia, which can be fatal if left 
untreated. However, the disorder is completely reversible within 
by early treatment with biotin (5–10 mg/kg/day) in combination 
with thiamine [from 100–200 mg (79) to 300–900 mg (78); 
Table 1], underscoring the critical nature of a timely diagnosis. 
Signs and symptoms usually appear during childhood (between 
the ages of 3 and 10 years), although onset of the disease can vary 
between newborn period and adulthood (78, 88).
The Amish lethal microcephaly (MCPHA; OMIM 607196), 
also known as thiamine metabolism dysfunction syndrome-3 
(THMD3; Table 1) (56), is caused by homozygous mutation in the 
SLC25A19 gene. Amish type microcephaly is a severe autosomal 
recessive metabolic disorder characterized by severe microcephaly 
apparent at birth, profoundly delayed psychomotor development, 
brain malformations, and episodic encephalopathy associated 
with lactic acidosis and α-ketoglutaric aciduria (89). The clinical 
management is achieved by administering a high-fat diet (81), 
which sustains the production of ATP by mitochondria primarily 
through fatty acid β-oxidation, bypassing PDH to directly enter 
the Krebs cycle. Importantly, the metabolic similarity of MCPHA 
to PDH deficiency (OMIM 312070) indicates the relevance of 
administering a low-carbohydrate diet to patients with MCPHA 
to avoid a risk of exacerbating the lactic acidemia.
A less severe variant of the disease, thiamine metabolism 
dysfunction syndrome 4 (THMD4; OMIM 613710), is similarly 
caused by a homozygous mutation in the SLC25A19 gene (Table 1). 
In THMD4, mitochondrial TPP uptake is reduced but not 
completely abolished. The disorder is characterized by childhood 
onset of episodic encephalopathy, causing transient neurologic 
dysfunction and a slight increase in cerebrospinal fluid (CSF) 
lactate levels during the acute phase of the disease. Most patients 
fully recover without therapeutic intervention; however, in some 
instances, mild residual weakness may persist (82).
Genetic defects in TPK1 (also known as THMD5) prevent 
the phosphorylation of thiamine to TPP, the active cofactor. It 
usually presents during childhood with acute encephalopathic 
episodes associated with increased serum and CSF lactate. These 
episodes result in progressive motor dysfunction (e.g., gait 
defects, ataxia, dystonia, and spasticity) associated with striatal, 
basal ganglial, and cerebellar regions of the brain, but cognition 
appeared to remain intact. Given that the phenotype is highly 
variable, it is likely that residual TPK1 activity and/or other 
cellular kinases (albeit at a lower extent and favored by the mass 
action of high thiamine doses) may also phosphorylate thiamine, 
thereby partly circumventing the metabolic block. This is based 
on the fact that i) some affected subjects improved with thiamine 
treatment [100–200 mg/day or 200 mg/twice daily (90, 91)] or 
with supplementation with thiamine and niacin, biotin, α-lipoic 
acid, and ketogenic diet (90), whereas others did not (83); and 
ii) deficiencies in other TPP-dependent enzymes, TKT and 
BCKADH, have not been observed in subjects with pathogenic 
mutations in TPK1 (83).
TABLE 1 | Genetic mutations affecting thiamine metabolism.
Name of disease Mutation Protein Age at onset Clinical symptoms Management (dose) 
(reference)
TRMA/Rogers 
syndrome
SLC19A2 THTR1 Birth to adolescence Megaloblastic anemia, diabetes mellitus, 
sensorineural deafness, optic atrophy, 
congenital heart defects, short stature
Thiamine (50–100 mg/day) (77)
Biotin–thiamine-
responsive basal ganglia 
disease
SLC19A3 THTR2 Birth to adolescence Episodic encephalopathy associated 
with febrile illness, seizures, external 
ophthalmoplegia, dysphagia, gait ataxia, 
bilateral lesions of the basal ganglia
– Biotin (5–10 mg/kg/day), 
thiamine (300–900 mg) (78)
– Biotin (5–10 mg/kg/day), 
thiamine (100–200 mg) (79)
Amish lethal 
microcephaly/THMD3
SLC25A19 Mitochondrial 
TPP carrier
Birth Episodic encephalopathy associated with 
lactic acidosis and alpha-ketoglutaric 
aciduria, microcephaly, delayed 
psychomotor development, seizures, 
increased urinary lactate
– Phenobarbital (for seizures) 
and physical therapy (80)
– High-fat diet (81)
Thiamine metabolism 
dysfunction syndrome 
4/THMD4 (progressive 
polyneuropathy type)
SLC25A19 MTPC Adolescence Episodic encephalopathy associated 
with febrile illness, transient neurologic 
dysfunction, residual weakness, 
progressive axonal polyneuropathy, 
bilateral striatal degeneration 
High-dose thiamine 
administered at the time of the 
study. Outcome not available 
(82)
Thiamine metabolism 
dysfunction syndrome 5 
(episodic encephalopathy 
type) THMD5
TPK1 Thiamine 
phosphokinase 1
Early childhood Episodic encephalopathy (Leigh-like) 
associated with high serum and CSF 
lactate with progressive neurologic and 
motor dysfunctions (gait disturbances, 
ataxia, dystonia, and spasticity, which, 
in some cases, may result in loss of 
ability to walk) triggered by infections. 
Cognitive function usually preserved; some 
developmental delay. Some patients may 
recover from some neurologic deficits; in 
others, the outcome is fatal.
Oral thiamine (100–200; 
500 mg/day) (83, 84)
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PATHOLOGY OF THIAMINE DEFICIENCY
As indicated above, the pathology of thiamine deficiency entails 
impaired energy-production from mitochondria in the form of 
ATP when using pyruvate-generating substrates (e.g., glucose) as 
well as increased oxidative stress (27). Under these conditions, 
glucose via glycolysis generates pyruvate, which cannot enter the 
Krebs cycle as acetyl-CoA due to the low activity of PDH. As 
such, pyruvate is transaminated to Ala or reduced to lactate via 
lactate dehydrogenase. This is consistent with the elevated lactate 
and organic acids observed in CSF, urine, and blood during 
thiamine deficiency (92–94).
Thiamine deficiency has been show to stabilize HIF-1α under 
normoxic conditions, thereby upregulating the expression of the 
glucose transporter GLUT1, VEGF, aldolase A, LDH, and THTR2 
(95). This stabilization might be achieved by the inhibition of prolyl 
hydroxylase by increased oxidative stress conditions originated 
from the lower TKT activity within the PPP. These changes may 
be accompanied by increased glycolysis and fatty acid oxidation 
to sustain the cellular energy needs. The latter process may ensue 
with the ultimate formation of acetyl-CoA, skipping the PDH-
catalyzed step. The increased flux of acetyl-CoA will then build 
up the levels of Krebs’ intermediates including fumarate and 
succinate (also inhibitors of prolyl hydroxylase), especially if 
the biotin-dependent pyruvate carboxylase cannot sustain the 
production of oxaloacetate, the most limiting substrate of the 
cycle. This also provides a biochemical explanation for the efficacy 
of the biotin and thiamine supplementation in the treatment of 
the biotin–thiamine-responsive basal ganglia disease. Although 
lower thiamine deficiency also affects α-KGDH activity, which 
is essential to maintain the levels of Glu, Asp, and GABA, its 
activity seems to be less affected than PDC, thus providing an 
operational Krebs cycle albeit at a lower efficiency. The lower 
activity of BCKADH can explain the higher levels of BCAA (Leu, 
Ile, and Val) in human fluids.
The human central nervous system has a high-energy demand, 
with 2% of the body mass overseeing about 20% of the total 
metabolic expenditure, the majority of which is spent on firing 
action potentials, on neuron communication, through chemical 
synapses, axon growth, and myelination (96). With glucose being 
the primary fuel for energy production in the brain, it is not 
surprising that mitochondrial dysfunction and the consequent 
impaired glucose metabolism have been associated with several 
neurological and neurodevelopmental conditions (97) and major 
psychiatric illnesses, such as depression (98) and schizophrenia 
(99). The neurological symptoms in thiamine deficiency are similar 
to defects of PDH, which most frequently present as Leigh-like 
syndrome with basal ganglia involvement. Therefore, the nervous 
system, which is highly specialized in the use of glucose for energy 
generation, seems to be most vulnerable to PDHC deficiency due 
to TPP depletion. In the brain, the lower mitochondrial ATP 
production will limit the maintenance of membrane potential via 
the action of the Na+,K+-ATPase, thereby compromising nerve 
conduction and chemical synapses. Moreover, the increased 
oxidative stress due to the lower TKT activity will damage 
critical biomolecules, initiating lipid peroxidation and oxidative 
damage to proteins resulting in fragmentation, posttranslational 
modifications, and cross-linkings. The modification of epitopes 
on normal, endogenous molecules may result in the activation of 
the microglia and immune cells, compounding oxidative stress-
mediated damage. The lower TKT has additional detrimental 
actions: by providing a suboptimal NADPH supply, biosynthetic 
reactions (nucleic acids and lipids) are undermined. This will 
limit not only cell proliferation but also the synthesis of fatty acids 
critical for the myelin sheath of axons. Thus, the combination of 
increased lipid peroxidation and the decreased fatty acid synthesis 
can result in demyelination, explaining some of the neurological 
issues caused by thiamine deficiency.
Altered thiamine metabolism has also been linked to 
growth of both neuronal soma and dendritic arbors in murine 
hippocampal neurons in culture. The individual silencing of 
TPK1 or each of the TPP carriers Slc25a19 and Slc19a3 in 
neurons significantly decreased dendrite arborization and soma 
size compared to controls (100). Conversely, overexpression of 
TPK1, Slc25a19, and Slc19a3 significantly reversed these changes, 
leading to increased dendritic branch length and number as 
well as soma size. Notably, these pathways are independent and 
nonredundant, as the overexpression of any of the proteins did 
not improve the dendritic damage caused by suppression of the 
other two. These findings are indicative of the crucial role that 
thiamine metabolism plays in soma and dendrite growth (100), 
and they are consistent with the microcephaly and neuronal 
damage reported in cases of thiamine deficiency.
In Adults
Symptoms and Consequences of Thiamine 
Deficiency
Thiamine deficiency can present with a broad range of 
neurological signs in children, such as anorexia, irritability, 
agitation, muscle pain, diminished or abolished deep tendon 
reflexes, ataxia, paralysis, and a progressively altered level 
of consciousness. Lactic acidosis may explain some of the 
generalized symptoms, including lethargy, irritability, anorexia, 
tachycardia, and tachypnea. These clinical manifestations are 
probably secondary to mitochondrial dysfunction in the heart 
and smooth muscle (particularly the gastrointestinal tract) and 
an autonomic nervous system insult (neurotransmitters). Others 
such as mood changes (agitation, confusion, and generalized 
malaise) may result from brain energy deficits as well as from 
a compromised synthesis of neurotransmitters (glutamate and 
GABA). Given the above-described varied clinical presentations, 
especially in children, any unexplained severe neurological signs 
or symptoms should raise the suspicion of thiamine deficiency 
[see Hiffler et al. (3) and references therein].
Generally, in blood from healthy adults, TPP levels <70 nmol/L 
are suggestive of thiamine deficiency [reference values: 70–180 
nmol/L; https://www.mayocliniclabs.com (101, 102)]. Thiamine 
levels have also been assessed in CSF, in the context of Alzheimer’s 
disease and in instances of SLC19A3 mutations (103, 104). 
Although no universally accepted reference values exist for CSF, 
thiamine levels of 5–7 nM are considered normal in adults (105).
Blood and CSF thiamine levels provide limited information when 
assessing the thiamine status of a subject, as they not necessarily 
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reflect thiamine metabolic function (102) or a direct association to 
its levels in the tissues. As such, assessments of erythrocytes’ TKT 
and, if available, that of other tissue-specific TPP-dependent enzymes 
(PDH, αKGDH) are considered gold standards (24, 26). Basic TKT 
activity is usually expressed as units per gram of hemoglobin (g Hb), 
but more importantly, the percentage of activation of TKT to TPP 
supplementation are calculated (with 0–15% considered normal). 
One study reported that the HPLC detection of TPP in whole blood 
or red blood cells is equally effective to the TKT activation ratio at 
determining thiamine deficiency (37).
The TKT activation ratio (red blood cells) and/or the activities 
of TPP-dependent enzymes (leukocytes, skin fibroblasts, and 
muscle biopsies) are usually accompanied by testing the levels 
of serum lactate and pyruvate, BCAAs, organic acids, as well as 
brain imaging. The only cases in which the evaluation of free 
thiamine in plasma/serum and CSF seems to provide a valuable 
diagnostic tool is when dealing with pathogenic mutations in 
SLC19A3 (104). Similarly, urinary excretion of thiamine is also 
not a reliable method for the assessment of its bodily levels as it is 
dependent on its intake and absorption. Generally, it is expressed 
per unit of creatinine to account for renal function, and age 
should be taken into account as normal values differ in children 
[120 nmol/mmol creatinine in 1–13 years old (105)] and adults 
[220 nmol/mmol creatinine in >18 years old (105)].
Unfortunately, early symptoms of thiamine deficiency are not 
pronounced or distinctive enough to warrant a direct diagnosis. 
They include loss of appetite, nausea, weakness, apathy, fatigue, 
irritation, sleep disturbances, anorexia, and abdominal discomfort 
(106). Furthermore, the identification of specific clinical symptoms 
of thiamine deficiency is problematic because it is obscured by 
the contribution of other confounding conditions (comorbidities) 
such as infections and/or multiple nutritional deficiencies.
The clinical classification of thiamine deficiency falls usually 
into dry (or neuritic, characterized by polyneuropathy, reduced 
knee jerk and other tendon reflexes, and progressive severe 
weakness of muscles) and wet (or cardiac, characterized by edema 
of the legs, trunk, and face; high cardiac output; ventricular 
failure; and pulmonary congestion). This classification is based 
on the amount of fluid that accumulates in the body due to 
factors like cardiac function and kidney lesions, among others 
(107). However, many cases of thiamine deficiency are amply 
systemic and encompass the nervous and cardiovascular system, 
as well as the gastrointestinal tract (with symptoms spanning 
from anorexia, abdominal pain, and constipation) (108). Long-
term consequences of severe thiamine deficiency are manifested 
by the appearance of hemorrhagic and/or necrotic lesions with 
neuronal and dendritic spine loss in the thalamus, hypothalamus, 
and cerebellum (109–111), as well as polyneuritis, peripheral 
edema, cardiac enlargement, and ophthalmoplegia (27).
When early, generalized thiamine deficiency is suspected, 
prompt administration of thiamine is advised and typically an 
effective treatment. A wide range of therapeutic approaches and 
thiamine doses are reported in the literature, spanning from 
1.5 to 600 mg/day (112), with 10–20 mg/day as divided doses 
for several weeks for mild polyneuropathy and 20–30 mg/day 
for moderate to severe, usually until after disappearance of 
symptoms (106). Generally, thiamine deficiency is approached 
with doses of 5–30 mg/day intravenously (IV) or intramuscularly 
(IM), three times daily, followed by 5–30 mg/day orally until 
after disappearance of symptoms (112). However, this approach 
is notably less effective for individuals with chronic forms of 
thiamine deficiency-related disorders involving encephalopathies 
(see the section Wernicke Encephalopathy) (113) or TPK1 
deficiencies. In the latter case, it would be worth to explore a 
treatment directly with TPP; however, it is not clear whether 
this phosphorylated thiamine form would cross the blood–brain 
barrier and/or reach subcellular targets such as PDH.
Wernicke Encephalopathy
Wernicke encephalopathy (WE) is a thiamine-deficiency-
related acute neuropsychiatric condition, often associated with 
alcohol abuse (114). It is characterized by ataxia, loss of muscle 
coordination, memory loss, confusion, and ocular abnormalities 
(ophthalmoplegia). Failure to timely diagnose the disease and 
the lack of an appropriate therapy result in death in 17% of 
the cases, while 84% will undergo permanent brain damage 
involving severe short-term memory loss and hallucinations 
[or Korsakoff ’s syndrome (KS)], residual syndrome in 
patients previously affected with WE (115). Because of the 
close association between these two conditions, they often get 
referred to as Wernicke–Korsakoff syndrome (WKS). Recently, 
it has been suggested that WE may be underdiagnosed (116), 
with similar incidence in both adults and children (117), with 
ratification of the diagnosis in 0.4–2.8% of postmortem cases, but 
recognized only in 32% and 6% of patients with and without 
alcoholism, respectively. In particular, it would be critical 
to consider WE in any patient showing two of the following 
characteristics: nutritional deficiency, cerebellar or oculomotor 
abnormalities, or impaired mental state or memory (116). 
Only 16% of the WE cases are expected to fully recover after 
thiamine supplementation. As oral absorption is highly variable 
and patient-dependent (116), parenteral treatment is highly 
recommended with daily doses of 100–200 mg thiamine (IV) for 
non-alcoholics and 500 mg (up to three administrations daily) 
for alcoholics (114).
A substantial body of literature has been published in the past 
>50 years regarding WE. A detailed description of the clinical 
features, pathophysiology, and treatment of this syndrome is 
beyond the scope of this review.
Depression
A number of studies have shown an inverse association between 
thiamine levels and symptoms of depression in adults. A cross-
sectional study on >1,500 elderly Chinese (age 50–70 years) 
showed that subjects with lower levels of erythrocyte thiamine 
(likely representing TPP bound to TKT) displayed more severe 
symptoms of depression (118). In this report, although no apparent 
differences were noted between individuals with and without 
depressive symptoms in dietary thiamine intake, the authors could 
not exclude errors in dietary assessment related to differences in 
food processing (118). In addition, other factors like diabetes, 
altered hormone profiles, and increased alcohol consumption 
observed in some individuals with depressive symptoms could 
play a critical role in the bioavailability of thiamine (118).
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A direct correlation between thiamine deficiency and 
symptoms of major depressive disorder (MDD) had been 
previously found in a population of 74 individuals with history 
of malnutrition (119). These findings were confirmed by another 
study involving 118 geriatric patients (120), although in this 
particular instance, no information about dietary thiamine 
intake was provided.
Additionally, Ghaleiha and colleagues explored the 
interventional effect of thiamine supplementation in thiamine-
deficient subjects with MDD in a 12-week, randomized, double-
blind clinical trial (121). The study concluded that symptoms 
of depression improved significantly in subjects with MDD 
following 6 weeks of thiamine supplementation compared to 
placebo.
Finally, positive mood changes (clearheadedness, increased 
energy and appetite, improved sleep patterns, and decreased 
fatigue) have been observed following thiamine supplementation 
in healthy elderly (16) as well as younger (122) women, 
compared to the same population assigned to the placebo 
group. Interestingly, while in the elderly population, a marginal 
deficiency of thiamine was reportedly due to the lack of a national 
thiamine enrichment policy for grains and cereals at the time 
of the study, in the case of younger women, a normal thiamine 
intake was recorded for all participants at baseline.
In Children
In children, thiamine deficiency presents with acute symptoms 
and very rapid onset, and in the vast majority of cases, it affect 
infants who are breast-fed by thiamine-deficient mothers or with 
thiamine-deficient formulas.
A pivotal study that highlighted the crucial role of thiamine 
as an essential nutrient for infant development and discussed 
how TD phenotype may be confused or overlooked with other 
diseases was based on an epidemiological investigation on 24- to 
39-month-old children presenting repeated vomiting, irritability, 
and lethargy, without major neurological abnormalities. All 
children who had consumed the same soy-based, thiamine-
deficient formula (<0.5 mg/g formula) suffered from language 
and motor development deficits compared to sex- and age-
matched children fed with other milk-based diets (123). Another 
study on the acute and long-term effects of thiamine-deficient 
formula-fed children who were not promptly diagnosed reported 
that a subset of patients (36%) died of cardiac and respiratory 
complications (124), and the remaining children developed 
intellectual disabilities, neurodevelopmental delay, and major 
motor dysfunction by the age of 9 (124). Recently, in another 
study by Harel et al. (125), more than 50% of a preschool children 
cohort, who were exposed to a thiamine-deficient diet for more 
than 1 month during the first 24 months of life, developed 
movement and motor skills difficulties compared to less than 
10% among children with appropriate thiamine intake.
Infantile Thiamine Deficiency
Infantile thiamine deficiency (ITD) manifests after 2–3 weeks of 
thiamine deprivation with initially milder symptoms (refusal to 
eat, vomiting, and irritability), followed by rapid deterioration, 
with a high fatality rate (106). Newborns who are severely 
thiamine deprived may develop infantile beriberi. The disorder 
is rare in developed countries, as it can be readily treated with 
thiamine supplementation (126). However, it remains a concern 
in developing countries among infants breast-fed by thiamine-
deficient mothers or fed with thiamine-deficient formula. 
Without proper thiamine supplementation, the deficiency is 
characterized by a rapid onset of symptoms involving vomiting, 
diarrhea, tachypnea, convulsions, ataxia, paralysis, cardiac 
dysfunction, and heart failure. In many cases, fatality occurs 
quickly (127). Those children who survive thiamine-deficiency-
related WE [see the section Wernicke Encephalopathy and 
Vasconcelos et al. (128)] continue to live with developmental 
disabilities including severe epilepsy, language impairment, loss 
of motor function (to varying degrees), and mental retardation 
(mild to profound) (124).
In two separate case reports, one newborn (2 months old) with 
early infantile Leigh-like SLC19A3 gene defect (129) and one 
(30 days old) with THTR2 deficiency (130) responded dramatically 
differently to thiamine supplementation. In the first case, the 
2-month-old infant initially presenting with fever, feeding 
difficulties, and complex partial seizures (129) subsequently 
developed a severe encephalopathy. MRI showed abnormalities 
in both cerebral hemispheres as well as in brainstem and 
cerebellum, basal ganglia, and thalamus. A diffuse volume loss 
was also noted in both hemispheres. At the biochemical level, 
metabolic acidosis was diagnosed. Despite a prompt therapeutic 
regimen consisting of thiamine (37.5 mg/kg) and biotin (10 mg/
kg) twice daily, the patient’s conditions never improved and he 
died at 4 months of age. The lack of response to treatment in 
this instance seems to suggest that its effectiveness is completely 
halted in the presence of a null mutation leading to a complete 
loss of function of the thiamine transporter in the early-onset 
form [see Table 1 in Alfadhel (129)].
In the second case report, the infant showed acute 
mitochondrial encephalopathy, accompanied by increased level 
of lactate in the blood and cerebrospinal fluid as well as abnormal 
levels of α-ketoglutarate in the urine. Cortico-subcortical lesions 
were visualized by MRI, some of which seemed to have appeared 
in the perinatal period (130). Within 48 h after administration 
of thiamine (100 mg/day), biotin (10 mg/day), and carnitine 
(300 mg/day), a remarkable improvement was observed in both 
clinical and biochemical outcomes (130). After discontinuing 
biotin, the patient remained stable for 6 months on thiamine 
supplementation (20 mg/kg/day) (130).
It is now widely established that less severe cases of ITD can be 
treated (to varying degrees) with early thiamine supplementation. 
In general, therapeutic recommended doses are 10–25 mg/daily 
IV or IM for 2 weeks, or 10–50 mg/daily orally, followed by 
5–10 mg/daily for 1 month (112).
Autism Spectrum Disorders
More recently, thiamine-based treatments have gained a great 
deal of attention as a therapeutic strategy for other developmental 
and neurological disorders linked to mitochondrial dysfunction. 
One such disorder is autism spectrum disorder (ASD), a group 
of complex neurological and developmental disabilities, with a 
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prevalence of 1 in 54 and 1 in 252, respectively, for males and 
females age 8 years in the United States (131). “Spectrum” refers 
to the wide heterogeneity and range of symptoms within three 
characteristic patterns: atypical cognitive profile, executive 
dysfunction, and unusually restricted or repetitive behavior 
(131). Individuals with ASD show severe cognitive and verbal 
impairments and experience challenges in the development of 
critical social communication skills.
Limited findings are available on the link between thiamine 
bioavailability and the development of autism. However, studies 
show that the consumption of herbal supplements rich in 
thiaminase during pregnancy (132) or alcohol exposure in utero 
(133) may predispose a fetus to thiamine deficiency during 
pregnancy and increased risk for ASD. A study conducted on rat 
pups nursed by thiamine-deficient dams displayed comparable 
findings, in which the offspring exhibited behavioral abnormalities 
consistent with ASD symptoms (134).
A number of hypotheses have been put forward on the 
pathophysiological mechanisms linking thiamine deficiency 
and ASD (135), including i) increased apoptosis, due to the link 
of thiamine with p53 (136, 137), Bcl-2 (138, 139), and caspases 
(140); ii) deregulation of the serotoninergic system (141, 142); and 
iii) increased oxidative stress, due to the putative role of thiamine 
in prostaglandin expression, decreased lipid peroxidation as 
well as expression of nitric oxide synthase (143, 144), and its 
involvement as a cofactor for TKT in the PPP, master regulator of 
NADPH homeostasis.
More interestingly, a subset of children with ASD has been 
characterized by PDH deficiency and mitochondrial dysfunction 
(145, 146), suggesting that thiamine deficiency may also ensue 
in PDH deficits or that a borderline thiamine intake would 
compound the preexistent PDH deficit, precipitating energy 
metabolism and leading to ASD in genetically predisposed 
individuals. Furthermore, a more recent study has shown 
decreased TPP levels in plasma from ASD children compared to 
healthy controls (147), suggesting either lower consumption or 
an impaired absorption from the gastrointestinal tract, providing 
a link between thiamine metabolism and the gut microbiome, 
which has been considered in the context of ASD (148). While 
there is no evidence to suggest that a sole deficiency in thiamine 
may result in ASD, it could certainly be a contributing element 
in concert with other epigenetic factors in the presence of an 
already predisposed genetic background.
Based on the finding that children with ASD seem to 
have an impairment in the catabolism and excretion of thiol-
containing heavy metals, Lonsdale et al. proposed that thiamine 
supplementation may be indicated for all children with ASD 
(149), with the idea that heavy metal toxicity can hamper 
TKT activity, increase oxidative stress, and, in turn, disrupt 
thiamine homeostasis. Hence, thiamine supplementation may, to 
some  extent, improve carbohydrate metabolism, mitochondrial 
function, and brain energy production (150). In that study, children 
with ASD were administered a thiamine derivative, bi-daily for 
2 months and noted improved communication skills, sociability, 
sensory/cognitive awareness, and behavior in 8 out of the 10 
children studied as well as reduction in urine arsenic and mercury 
levels (149). In a separate, double-blind, placebo-controlled study, 
researchers noted decreased oxidative stress, increased ATP in 
plasma and NADH and NADPH production in red blood cells, 
and improved PGI-R (Parent Global Impressions—Revised) scores 
in hyperactivity, tantrum, and receptive language categories in 
autistic children administered vitamin/mineral supplementation, 
which included thiamine, over a 3-month period (151).
These pilot studies provide some support for a thiamine-
based approach as a therapeutic intervention for ASD. However, 
further studies are warranted to clarify the role and specificity 
of thiamine supplementation for the management of the diverse 
and extensive range of ASD features.
Depression in Children and Child-Bearing Women
To our knowledge, to date, only one study has investigated the 
contribution of thiamine levels to pediatric depression (152). 
Surprisingly, and opposite to findings in adults, this study found 
a direct correlation between thiamine intake and depressive 
symptoms in Spanish schoolchildren (7–9 years old).
Although a fairly common condition among teenagers, 
little is known about depression and its treatment in children 
12 years old and younger (153). Depression in children is often 
overlooked and oftentimes mistaken by teachers and parents 
and labeled as laziness, learning disabilities, or belligerence 
(154). Similarly, the “acting out” behavior observed in pediatric 
depression is often labeled as bullying, rebellion, or even 
psychotic behavior (154).
The effects of thiamine supplementation might be significant 
as palliative treatment in postpartum depression (PPD) and have 
a critical role on the infant’s subsequent cognitive development. 
PPD has been associated with an increased risk of developing 
learning disabilities, Attention-Deficit/Hyperactivity Disorder 
(ADHD), and anxiety disorders in toddlers, which makes PPD 
a critical concern for both mother and infant (155). Nikseresht 
et al. investigated the therapeutic effects of Zn2+, Mg2+, and 
TPP supplementation in a PPD mouse model. Improvements 
in depressive symptoms and anxiety-like behaviors (tested by 
forced swimming test and elevated plus-maze), as well as total 
antioxidant capacity, were noted in the dams when the nutrients 
were administered on postpartum day 3 (156). Taken together, 
these findings indicate that thiamine supplementation may be a 
promising therapeutic strategy for PPD. However, future studies 
should address the role of thiamine in PPD independently and 
whether supplementation in instances of PPD positively impacts 
infant development.
CONCLUSIONS AND FUTURE 
PERSPECTIVES
Thiamine deficiency, regardless of the underlying mechanism 
(genetic or epigenetic), impairs critical TPP-dependent 
enzymes involved in intermediary metabolism and antioxidant 
defenses. The consequent decrease in ATP production and 
increased oxidative stress result in neurological deficits, 
which become especially detrimental during critical 
windows of neurodevelopment. In the recent years, thiamine 
supplementation has been contemplated, with some success, 
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as a therapeutic approach for neurodevelopmental disorders, 
including ASD and major psychiatric disorders (i.e., depression). 
However, the vast heterogeneity of the pathogenic mechanisms 
underlying these conditions, along with the difficulty of 
diagnosis and the assumption that diets from developed 
countries supply enough thiamine to match the caloric intake 
(including perinatal periods), has not prompted enough research 
to address the role and effects of thiamine supplementation 
as a therapeutic strategy in the context of neurodevelopment/
neurodegeneration. Of note, and an often overlooked issue, 
is the lack of incorporation of antioxidants into supplemental 
treatments that are deemed critical to minimize the thiamine-
deficiency-dependent oxidative-stress-derived damage. This 
will also allow to shed light on the contribution of oxidative 
stress versus mitochondrial dysfunction to the morbidity of 
neurodegenerative disorders.
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